| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790390 | Urologic Oncology: Seminars and Original Investigations | 2017 | 6 Pages |
Abstract
Experimental validation of the down expression of C3a was well succeeded using a commercial ELISA kit. Complement system fragment C3a is down expressed in patients with SCCP. Besides, C3a is also low expressed in the plasma of patients with initial prostate cancer when compared to healthy subjects. These results suggest that the innate immune response might be suppressed in patients with these malignancies.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Paulo M.D., Marilza de M. Ph.D., Antonio Augusto Ph.D., M.D., Luciano M.S., Leandro M.D., Fulvio Ph.D., Maria Helena M.D., Ph.D., Gilda Ph.D.,